Literature DB >> 24069508

EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma.

Savita Sankar1, Nicholas C Gomez, Russell Bell, Mukund Patel, Ian J Davis, Stephen L Lessnick, Wen Luo.   

Abstract

The gene encoding EWS (EWSR1) is involved in various chromosomal translocations that cause the production of oncoproteins responsible for multiple cancers including Ewing sarcoma, myxoid liposarcoma, soft tissue clear cell sarcoma, and desmoplastic small round cell sarcoma. It is well known that EWS fuses to FLI to create EWS/FLI, which is the abnormal transcription factor that drives tumor development in Ewing sarcoma. However, the role of wild-type EWS in Ewing sarcoma pathogenesis remains unclear. In the current study, we identified EWS-regulated genes and cellular processes through RNA interference combined with RNA sequencing and functional annotation analyses. Interestingly, we found that EWS and EWS/FLI co-regulate a significant cluster of genes, indicating an interplay between the 2 proteins in regulating cellular functions. We found that among the EWS-down-regulated genes are a subset of neuronal genes that contain binding sites for the RE1-silencing transcription factor (REST or neuron-restrictive silencer factor [NRSF]), neuron-restrictive silencer element (NRSE), suggesting a cooperative interaction between REST and EWS in gene regulation. Co-immunoprecipitation analysis demonstrated that EWS interacts directly with REST. Genome-wide binding analysis showed that EWS binds chromatin at or near NRSE. Furthermore, functional studies revealed that both EWS and REST inhibit neuronal phenotype development and oncogenic transformation in Ewing sarcoma cells. Our data implicate an important role of EWS in the development of Ewing sarcoma phenotype and highlight a potential value in modulating EWS function in the treatment of Ewing sarcoma and other EWS translocation-based cancers.

Entities:  

Keywords:  EWS; Ewing sarcoma; REST; neuronal phenotype; oncogenic transformation

Year:  2013        PMID: 24069508      PMCID: PMC3782006          DOI: 10.1177/1947601913489569

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  58 in total

1.  The pro-oncoprotein EWS (Ewing's Sarcoma protein) interacts with the Brn-3a POU transcription factor and inhibits its ability to activate transcription.

Authors:  G Ruth Thomas; David S Latchman
Journal:  Cancer Biol Ther       Date:  2002 Jul-Aug       Impact factor: 4.742

2.  Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.

Authors:  J T Wu; A J Erickson; K C Tsao; T L Wu; C F Sun
Journal:  Ann Clin Lab Sci       Date:  2000-04       Impact factor: 1.256

3.  EWS/ETS fusion genes induce epithelial and neuroectodermal differentiation in NIH 3T3 fibroblasts.

Authors:  M A Teitell; A D Thompson; P H Sorensen; H Shimada; T J Triche; C T Denny
Journal:  Lab Invest       Date:  1999-12       Impact factor: 5.662

4.  Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation.

Authors:  Y W Goh; D V Spagnolo; M Platten; P Caterina; C Fisher; A M Oliveira; A G Nascimento
Journal:  Histopathology       Date:  2001-11       Impact factor: 5.087

5.  Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance.

Authors:  S Hahm; T M Mizuno; T J Wu; J P Wisor; C A Priest; C A Kozak; C N Boozer; B Peng; R C McEvoy; P Good; K A Kelley; J S Takahashi; J E Pintar; J L Roberts; C V Mobbs; S R Salton
Journal:  Neuron       Date:  1999-07       Impact factor: 17.173

6.  EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing.

Authors:  L Yang; H A Chansky; D D Hickstein
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

7.  The EWS protein is dispensable for Ewing tumor growth.

Authors:  H Kovar; G Jug; C Hattinger; L Spahn; D N Aryee; P F Ambros; A Zoubek; H Gadner
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

Review 8.  Knockout of REST/NRSF shows that the protein is a potent repressor of neuronally expressed genes in non-neural tissues.

Authors:  F S Jones; R Meech
Journal:  Bioessays       Date:  1999-05       Impact factor: 4.345

9.  A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker.

Authors:  J M Coulson; J L Edgson; P J Woll; J P Quinn
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

10.  The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.

Authors:  Stephen L Lessnick; Caroline S Dacwag; Todd R Golub
Journal:  Cancer Cell       Date:  2002-05       Impact factor: 31.743

View more
  12 in total

1.  Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription.

Authors:  Linyu Zuo; Guanwei Zhang; Matthew Massett; Jun Cheng; Zicong Guo; Liang Wang; Yifei Gao; Ru Li; Xu Huang; Pilong Li; Zhi Qi
Journal:  Nat Commun       Date:  2021-03-05       Impact factor: 14.919

2.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

3.  A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Authors:  Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

4.  Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Authors:  Savita Sankar; Emily R Theisen; Jared Bearss; Timothy Mulvihill; Laura M Hoffman; Venkataswamy Sorna; Mary C Beckerle; Sunil Sharma; Stephen L Lessnick
Journal:  Clin Cancer Res       Date:  2014-06-24       Impact factor: 12.531

5.  Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis.

Authors:  W Luo; C Xu; J Ayello; F Dela Cruz; J M Rosenblum; S L Lessnick; M S Cairo
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

6.  EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma.

Authors:  John Fadul; Russell Bell; Laura M Hoffman; Mary C Beckerle; Michael E Engel; Stephen L Lessnick
Journal:  Genes Cancer       Date:  2015-03

7.  Targeting Glutathione S-transferase M4 in Ewing sarcoma.

Authors:  Rupeng Zhuo; Kenneth M Kosak; Savita Sankar; Elizabeth T Wiles; Ying Sun; Jianxing Zhang; Janet Ayello; Glenn D Prestwich; Paul J Shami; Mitchell S Cairo; Stephen L Lessnick; Wen Luo
Journal:  Front Pediatr       Date:  2014-08-06       Impact factor: 3.418

8.  REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature.

Authors:  Shavali Shaik; Bridget Kennis; Shinji Maegawa; Keri Schadler; Yang Yanwen; Keri Callegari; Rishi R Lulla; Stewart Goldman; Javad Nazarian; Veena Rajaram; Jason Fangusaro; Vidya Gopalakrishnan
Journal:  Oncotarget       Date:  2017-12-28

9.  EWS Knockdown and Taxifolin Treatment Induced Differentiation and Removed DNA Methylation from p53 Promoter to Promote Expression of Puma and Noxa for Apoptosis in Ewing's Sarcoma.

Authors:  Mohammad Motarab Hossain; Swapan Kumar Ray
Journal:  J Cancer Ther       Date:  2014-10-28

Review 10.  Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.

Authors:  Emily R Theisen; Kathleen I Pishas; Ranajeet S Saund; Stephen L Lessnick
Journal:  Oncotarget       Date:  2016-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.